Skip to main content
. Author manuscript; available in PMC: 2010 Jan 4.
Published in final edited form as: Biol Blood Marrow Transplant. 2008 Dec;14(12):1365–1372. doi: 10.1016/j.bbmt.2008.09.015

Table 1.

Patient demographic and transplant characteristics (N=142)

Patient Characteristic Frequency (%)
Age at transplantation <20 13 (9%)
(years) 20–39 28 (20%)
40–59 78 (55%)
≥60 23 (16%)
Median age = 47
Gender: Female 52 (37%)
Male 90 (63%)
Race: African American 6 (4%)
Caucasian 114 (80%)
Hispanic 7 (5%)
Other 13 (9%)
Not available 2 (1%)
Diagnosis Acute myeloid leukemia 52 (37%)
Myelodysplastic syndrome 29 (20%)
Chronic myeloid leukemia 19 (13%)
Non-Hodgkins lymphoma 13 (9%)
Acute lymphocytic leukemia 8 (6%)
Multiple Myeloma 6 (4%)
Chronic lymphocytic leukemia 3 (2%)
Aplastic anemia 5 (4%)
Other 7 (5%)
Donor type Allogeneic 59 (42%)
Autologous 17 (12%)
Unrelated donor 66 (46%)
Conditioning regimen Reduced intensity regimens (200cGy*) 37 (26%)
Myeloablative: CY/TBI 12–13.5 Gy 25 (18%)
Myeloablative: BU, CY only 61 (43%)
Other myeloablative regimens 19 (13%)
Baseline serum creatinine (mg/dL) Median (5th to 95th percentile) 0.9 (0.5–1.3)
*

cGy: centigray;

CY: cyclophosphamide;

BU: busulfan;

TBI: total body irradiation